{"entity":{"id":"epicentrx","kind":"company","name":"EpicentRx","aka":["EpicentRx, Inc."],"tldr":"EpicentRx is a United States-based biotechnology company running 3 late-stage cancer trials in sarcomas, head and neck squamous cell carcinoma and small-cell lung cancer.","summary":"EpicentRx, based in La Jolla, the United States, is a biotechnology company. EpicentRx is a clinical-stage company developing therapies for inflammatory diseases and supportive care conditions, including an oncolytic virus immunotherapy and a small molecule for treatment-related toxicities. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3) in sarcomas, head and neck squamous cell carcinoma, small-cell lung cancer and non-small-cell lung cancer. The largest, NCT05566041 (A Phase 3, Controlled, Open-label, Global Randomised Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer), plans to enrol 292 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.epicentrx.com"},{"label":"ClinicalTrials.gov: trials led by EpicentRx","url":"https://clinicaltrials.gov/search?lead=EpicentRx%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["sarcoma","head-and-neck","sclc","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05966194","nct05566041","nct04673942"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"La Jolla","country":"US","companyType":"biotech","website":"https://www.epicentrx.com","investors":[],"funding":[]},"route":"/companies/epicentrx/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"trial":[{"id":"nct05566041","kind":"trial","name":"A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer","route":"/trials/nct05566041/"},{"id":"nct04673942","kind":"trial","name":"A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors","route":"/trials/nct04673942/"},{"id":"nct05966194","kind":"trial","name":"RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer","route":"/trials/nct05966194/"}]}}